April 2021 in “Journal of Investigative Dermatology” Spironolactone safely and effectively treats hair loss in female scarring alopecia patients.
22 citations
,
May 2011 in “European Journal of Cancer” The drug combination was safe and showed promise in treating advanced tumors.
April 2019 in “Journal of Investigative Dermatology” Sandalore®, a synthetic scent, improved hair loss and satisfaction in women with telogen effluvium.
Ritlecitinib is a new treatment for severe hair loss in people 12 and older.
January 2022 in “Current Enzyme Inhibition” New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.
July 2026 in “Journal of Medicinal Chemistry” A new drug strategy improves hair loss treatment with better results and safety.
6 citations
,
April 2013 in “Journal of Investigative Dermatology” Spironolactone might lower the chance of getting rosacea.
8 citations
,
December 2007 in “Journal of Thoracic Oncology” Erlotinib can cause significant but temporary hair loss in lung cancer patients.
19 citations
,
January 2016 in “Annals of Dermatology” Dutasteride is safe and effective for treating hair loss, but may decrease libido.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
64 citations
,
June 2009 in “Journal of The American Academy of Dermatology” Oral dutasteride can potentially treat frontal fibrosing alopecia in postmenopausal women, with some patients showing disease arrest and hair regrowth.
5 citations
,
January 2024 in “Journal of Cancer” The treatment combination is effective and generally safe for lung cancer.
January 1993 in “Проблемы Эндокринологии” Spironolactone effectively reduces symptoms of hyperandrogenism but has some side effects.
August 2022 in “International Journal of Dermatology” Low-dose oral and sublingual minoxidil seem safe for children with hair disorders.
2 citations
,
August 2014 in “PubMed” Losartan may help treat Postural Orthostatic Tachycardia Syndrome (POTS) symptoms.
July 2024 in “Journal of Investigative Dermatology” A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.
2 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib improves hair regrowth in alopecia areata over 24 months.
1 citations
,
July 2024 in “Journal of the European Academy of Dermatology and Venereology” Oral dutasteride is effective and safe for treating frontal fibrosing alopecia.
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
December 2022 in “Scientific Reports” Compound 4 is a promising treatment for hair loss with low toxicity.
March 2026 in “Brazilian Journal of Animal and Environmental Research” Deslorelin can help control reproduction and improve hair growth in German Spitz dogs.
34 citations
,
July 2011 in “International journal of pharmaceutics” Ion-paired risedronate significantly increases skin penetration without irritation compared to risedronate alone.
Spironolactone effectively treats hormonal acne, hair loss, and excess hair growth in women.
February 2024 in “Practical Diabetes” Spironolactone helps reduce hospital visits and death from heart issues, lowers blood pressure, but has unclear effects on heart failure with normal heart pump function and can cause high potassium and breast enlargement in men.
A bald man grew hair on his head after taking a drug called diazoxide, but lost it again when he stopped the medication.
4 citations
,
December 1997 in “Clinical Endocrinology” Spironolactone may help reduce hair loss in androgenic alopecia.
June 2025 in “British Journal of Dermatology” Low-dose oral minoxidil is increasingly used by dermatologists in the UK and Ireland to treat various hair loss conditions.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in severe alopecia areata patients.
January 2004 in “Drug Development and Industrial Pharmacy” GI197111X is best dissolved in Capmul MCM for trials.